This study aims to conduct a randomized, double blind, randomised controlled multicentre trial of sirolimus drug coated balloon versus standard percutaneous transluminal angioplasty for the treatment of below the knee arterial disease.
The burden of limb loss as a result of peripheral arterial disease (PAD) is high and this problem is set to worsen globally. Treatment of PAD primarily involves revascularisation of the limb. Angioplasty as a first line strategy of revascularization over surgical procedures has been adopted by most vascular centers. Local drug delivery using drug coated balloons (DCB) during angioplasty for PAD can successfully deliver effective local tissue concentrations of anti-proliferative drugs to the lesions in the artery involved in the PAD. This offers the potential for sustained anti-restenotic efficacy. Randomized trials have shown superiority of Paclitaxel DCBs over just plain-balloon angioplasty for treatment of PAD, and DCB is now considered the standard of care. However, a recent meta-analyses which showed increased mortality at two years in patients treated with paclitaxel DCBs have called into question the safety of paclitaxel based DCBs. Alternative drugs for DCBs are therefore urgently needed and sirolimus offers an attractive alternative. Compared to Paclitaxel, sirolimus is cytostatic in its mode of action with a high margin of safety. It has a high transfer rate to the vessel wall and has been shown to effectively inhibit neointimal hyperplasia in the porcine coronary model. In the coronary artery interventions, preliminary clinical studies using Sirolimus DCBs have also shown excellent procedural and 6 month patency.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
219
For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty
Khoo Teck Puat Hospital
Singapore, Singapore
RECRUITINGPrimary patency at 6 months
Primary patency rate at 6 months defined as proportion of subjects with duplex ultrasonography-derived peak systolic velocity ratio of ≤ 2.4 (in absence of target lesion revascularisation)
Time frame: 6 months
Device and procedure related deaths
Proportion of device and procedure related deaths
Time frame: 1,6,12 and 24 Months
All-cause death
Proportion of subjects died by any-cause
Time frame: 1,6,12 and 24 Months
Major target limb amputation
Proportion of subjects with major target limb amputation
Time frame: 6,12 and 24 Months
Target vessel thrombosis
Proportion of subjects with target vessel thrombosis
Time frame: From day 0 to day 14
Proportion of subjects who experienced either death at 6 month or major target limb amputation at 6 month or target vessel thrombosis within 14 days.
Proportion of subjects who experienced either death at 6 month or major target limb amputation at 6 month or target vessel thrombosis within 14 days.
Time frame: Day 0 to day 14, 6 Months
Occurrence of adverse events (AEs), serious AEs and AEs related to device and procedure
Occurrence of adverse events (AEs), serious AEs and AEs related to device and Occurrence of adverse events (AEs), serious AEs and AEs related to device and procedure
Time frame: From Day 0 to 24 Months Follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
National University Hospital
Singapore, Singapore
RECRUITINGNg Teng Fong General Hospital
Singapore, Singapore
NOT_YET_RECRUITINGSengkang General Hospital
Singapore, Singapore
RECRUITINGSingapore General Hospital
Singapore, Singapore
RECRUITINGTan Tock Seng Hospital
Singapore, Singapore
RECRUITINGKaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
RECRUITINGKaoshiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
RECRUITINGFar Eastern Memorial Hospital
New Taipei City, Taiwan
RECRUITINGTaipei Tzuchi Hospital
New Taipei City, Taiwan
RECRUITING...and 10 more locations
Procedural Success
Proportion of subjects with procedural success during hospital stay
Time frame: From Day 1 to discharge up to maximum of 30 days
Proportion of subjects who are free from clinically-driven Target Lesion Revascularization (TLR)
Proportion of subjects who are free from clinically-driven TLR
Time frame: 6,12 and 24 Months
Proportion of subjects who are free from clinically-driven Target Vessel Revascularization (TVR)
Proportion of subjects who are free from clinically-driven Target Vessel Revascularization (TVR)
Time frame: 6,12 and 24 Months
Primary patency
Primary patency rate at 12 and 24 months
Time frame: 12 and 24 Months
Restenosis
Proportion of subjects with restenosis
Time frame: 6, 12 and 24 Months
Subjects who are free from MAE
Proportion of subjects who are free from MAE
Time frame: 6 Months
Amputation-free survival
Amputation-free survival
Time frame: 6, 12 and 24 Months
Clinical Success
Proportion of subjects with clinical Success at 6, 12 and 24 months, Clinical success is defined as Improvement in Rutherford classification compared to the pre-procedure Rutherford classification
Time frame: 6, 12 and 24 Months
Device success
Proportion of subjects with device success at day 1
Time frame: Day 1
Technical success
Proportion of subjects with technical success at day 1
Time frame: Day 1
Wound assessment (if any)
Wound assessment (if any)
Time frame: 1, 6, 12, 24 Months
Toe Pressure or ABPI assessment
Toe Pressure or ABPI assessment
Time frame: 6, 12, 24 Months